December 31, 2025
Headlines

neurodegenerative diseases

AC Immune says Parkinson’s drug slows progression

AC Immune says Parkinson’s drug slows progression

DRRA03 mins

Swiss biotech AC Immune has said that its vaccine-like alpha-synuclein-targeted immunotherapy has shown promise in slowing down the progression of Parkinson’s disease. The results of the phase 2 VacSYn trial of ACI-7104.056 in patients with early-stage Parkinson’s have shown that the immunotherapy can reduce disease-related biomarkers – namely alpha-synuclein levels in the cerebrospinal fluids (CSF)…

Read More
Bayer starts pivotal Parkinson’s cell therapy trial

Bayer starts pivotal Parkinson’s cell therapy trial

DRRA03 mins

Bayer’s much-anticipated stem cell therapy for Parkinson’s disease is gathering momentum, with dosing in phase 3 trials now underway. The first patient has already been treated with bemdaneprocel, a one-shot treatment designed to replace the dopamine-producing neurons that degenerate in Parkinson’s, which is being developed by Bayer’s BlueRock Therapeutics subsidiary. Meanwhile, Bayer is also making…

Read More